Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes

International Journal of Obesity volume 30, pages 439–446 (2006)Cite this article

Abstract

Objective:

The purpose of this study was to determine the relationships between adipocyte hormones acylation stimulating protein (ASP), adiponectin, complement C3 (C3) (ASP precursor) and insulin, C-reactive protein (CRP), lipid profiles and insulin resistance in lean vs obese type 2 diabetes subjects.

Subjects:

Lean type 2 diabetes subjects (DL n=27) vs obese type 2 diabetes subjects (DO n=55) were compared to age-matched nondiabetic groups (Obese, OB n=55 and control, CTL n=50).

Results:

The DO group demonstrated significant increases in plasma ASP and C3 with decreases in plasma adiponectin as compared to CTL. Interestingly, these increases in ASP and C3 were as high, or greater, in the DL group in spite of normal weight. By contrast adiponectin in the DL group was comparable to CTL, in spite of marked insulin resistance. C3 correlated with insulin, glucose and homeostasis model assessment of insulin resistance (HOMA-IR); ASP correlated with body mass index (BMI), glucose, insulin and plasma lipid parameters (non-esterified fatty acids (NEFA), triglyceride, cholesterol and apolipoprotein B). Adiponectin correlated with BMI, glucose, NEFA, triglyceride, high-density lipoprotein cholesterol and apolipoprotein A1 but not HOMA-IR, ASP or C3. CRP correlated only with HOMA-IR.

Conclusion:

Increased ASP and C3 are both associated with diabetes and related lipid factors but are not regulated coordinately. Adiponectin appears to be more closely related to body size (decreased in obese subjects) than insulin resistance in these subjects.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Gong D, Yang R, Munir KM, Horenstein RB, Shuldiner AR . New progress in adipocytokine research. Curr Opin Endocrinol Diab 2003; 10: 115–121.

    Article  CAS  Google Scholar 

  2. Kalant D, Maslowska M, Scantlebury T, Wang H, Cianflone K . Control of lipogenesis in adipose tissue and the role of acylation stimulating protein. Can J Diab 2003; 27: 154–171.

    CAS  Google Scholar 

  3. Jazet IM, Pijl H, Meinders AE . Adipose tissue as an endocrine organ: impact on insulin resistance. Neth J Med 2003; 61: 194–212.

    CAS  PubMed  Google Scholar 

  4. Havel PJ . Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002; 13: 51–59.

    Article  CAS  PubMed  Google Scholar 

  5. Cianflone K, Sniderman AD, Walsh MJ, Vu H, Gagnon J, Rodriguez MA . Purification and characterization of acylation stimulating protein. J Biol Chem 1989; 264: 426–430.

    CAS  PubMed  Google Scholar 

  6. Baldo A, Sniderman AD, St-Luce S, Avramoglu RK, Maslowska M, Hoang B et al. The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J Clin Invest 1993; 92: 1543–1547.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Cianflone K, Xia Z, Chen LY . Critical review of Acylation Stimulating Protein physiology in humans and rodents. Biochim Biophys Acta 2003; 1609: 127–143.

    Article  CAS  PubMed  Google Scholar 

  8. Bhakdi S, Torzewski M, Klouche M, Hemmes M . Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19: 2348–2354.

    Article  CAS  PubMed  Google Scholar 

  9. Ebeling P, Teppo AM, Koistinen HA, Koivisto VA . Concentration of the complement activation product, acylation-stimulating protein is related to C-reactive protein in patients with type 2 diabetes. Metabolism 2001; 50: 283–287.

    Article  CAS  PubMed  Google Scholar 

  10. Cianflone K, Roncari DAK, Maslowska M, Baldo A, Forden J, Sniderman AD . The adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis. Biochemistry 1994; 33: 9489–9495.

    Article  CAS  PubMed  Google Scholar 

  11. Maslowska M, Scantlebury T, Germinario R, Cianflone K . Acute in vitro production of ASP in differentiated adipocytes. J Lipid Res 1997; 38: 21–31.

    Google Scholar 

  12. Scantlebury T, Maslowska M, Cianflone K . Chylomicron specific enhancement of acylation stimulating protein (ASP) and precursor protein C3 production in differentiated human adipocytes. J Biol Chem 1998; 273: 20903–20909.

    Article  CAS  PubMed  Google Scholar 

  13. Scantlebury T, Sniderman AD, Cianflone K . Retinoic acid regulation of acylation stimulating protein (ASP) and complement C3 in human adipocytes. Biochem J 2001; 356: 445–452.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Cianflone K, Zakarian R, Couillard C, Delplanque B, Despres JP, Sniderman AD . Fasting acylation stimulating protein is predictive of postprandial triglyceride clearance. J Lipid Res 2004; 45: 124–131.

    Article  CAS  PubMed  Google Scholar 

  15. Murray I, Sniderman AD, Cianflone K . Enhanced triglyceride clearance with intraperitoneal human acylation stimulating protein (ASP) in C57Bl/6 mice. Am J Physiol Endocrinol Metab 1999; 277 (Part 1): E474–E480.

    Article  CAS  Google Scholar 

  16. Saleh J, Christou N, Cianflone K . Regional specificity of ASP binding in human adipose tissue. Am J Physiol 1999; 276 (Part 1): E815–E821.

    CAS  PubMed  Google Scholar 

  17. Murray I, Sniderman AD, Cianflone K . Mice lacking acylation stimulating protein (ASP) have delayed postprandial triglyceride clearance. J Lipid Res 1999; 40: 1671–1676.

    CAS  PubMed  Google Scholar 

  18. Murray I, Sniderman AD, Havel PJ, Cianflone K . Acylation stimulating protein (ASP) deficiency alters postprandial and adipose tissue metabolism in male mice. J Biol Chem 1999; 274: 36219–36225.

    Article  CAS  PubMed  Google Scholar 

  19. Xia Z, Stanhope KL, Digitale E, Simion O-M, Chen LY, Havel PJ et al. ASP deficiency results in increased energy expenditure in mice. J Biol Chem 2004; 279: 4051–4057.

    Article  CAS  PubMed  Google Scholar 

  20. Murray I, Havel PJ, Sniderman AD, Cianflone K . Reduced body weight, adipose tissue, and leptin levels despite increased energy intake in female mice lacking acylation-stimulating protein. Endocrinology 2000; 141: 1041–1049.

    Article  CAS  PubMed  Google Scholar 

  21. Xia Z, Sniderman AD, Cianflone K . Acylation-stimulating protein (ASP) deficiency induces obesity resistance and increased energy expenditure in ob/ob mice. J Biol Chem 2002; 277: 45874–45879.

    Article  CAS  PubMed  Google Scholar 

  22. Ukkola O, Santaniem M . Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med 2002; 80: 696–702.

    Article  CAS  PubMed  Google Scholar 

  23. Chan JC, Ng MC, Critchley JA, Lee SC, Cockram CS . Diabetes mellitus – a special medical challenge from a Chinese perspective. Diabetes Res Clin Pract 2001; 54 (Suppl 1): S19–S27.

    Article  PubMed  Google Scholar 

  24. Zhai F, Fu D, Du S, Ge K, Chen C, Popkin BM . What is China doing in policy-making to push back the negative aspects of the nutrition transition? Public Health Nutr 2003; 5: 269–273.

    Google Scholar 

  25. Ylitalo K, Porkka KV, Meri S, Nuotio I, Suurinkeroinen L, Vakkilainen J et al. Serum complement and familial combined hyperlipidemia. Arteriosclerosis 1997; 129: 271–277.

    Article  CAS  Google Scholar 

  26. Ylitalo K, Pajukanta P, Meri S, Cantor RM, Mero-Matikainen N, Vakkilainen J et al. Serum C3 but not plasma acylation-stimulating protein. Is elevated in Finnish patients with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2001; 21: 838–843.

    Article  CAS  PubMed  Google Scholar 

  27. Saleh J, Summers LKM, Cianflone K, Fielding BA, Sniderman AD, Frayn KN . Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. J Lipid Res 1998; 39: 884–891.

    CAS  PubMed  Google Scholar 

  28. Kalant D, Phelis S, Fielding BA, Frayn KN, Cianflone K, Sniderman AD . Increased postprandial fatty acid trapping in subcutaneous adipose tissue in obese women. J Lipid Res 2000; 41: 1963–1968.

    CAS  PubMed  Google Scholar 

  29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.

    Article  CAS  PubMed  Google Scholar 

  30. Friedewald WT, Levy RI, Fredrickson DS . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.

    CAS  PubMed  Google Scholar 

  31. World Health Organization Expert Committee. Second report on diabetes mellitus, (Technical Report Series), World Health Organization: Geneva, Switzerland, 1980, pp. 646–651.

  32. World Health Organization. The Asia–Pacific Perspective: Redefining obesity and its treatment. World Health Organization: Geneva, Switzerland, 2000.

  33. Kotler DP, Ionescu G, Johnson JA, Inada Y, He Q, Engelson ES et al. Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy. Clin Infect Dis 2003; 37 (Suppl 2): S47–S51.

    Article  CAS  PubMed  Google Scholar 

  34. Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone K . Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003; 88: 1594–1602.

    Article  CAS  PubMed  Google Scholar 

  35. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57–58.

    Article  CAS  PubMed  Google Scholar 

  36. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226–228.

    Article  CAS  PubMed  Google Scholar 

  37. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376–380.

    Article  CAS  PubMed  Google Scholar 

  38. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Throm Vasc Biol 2000; 20: 1595–1599.

    Article  CAS  Google Scholar 

  39. Yatagai T, Nagasaka S, Taniguchi A, Fukushima M, Nakamura T, Kuroe A et al. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 2003; 52: 1274–1278.

    Article  CAS  PubMed  Google Scholar 

  40. Zietz B, Herfarth H, Paul G, Ehling A, Muller-Ladner U, Scholmerich J et al. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett 2003; 545: 103–104.

    Article  CAS  PubMed  Google Scholar 

  41. Pellme F, Smith U, Funahashi T, Matsuzawa Y, Brekke H, Wiklund O et al. Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 2003; 52: 1182–1186.

    Article  CAS  PubMed  Google Scholar 

  42. Valsamakis G, Chetty R, McTerman PG, Al-Daghri NM, Barnett AH, Kumar S . Fasting serum adiponectin concentration is reduced in Indo-Asian subjects and is related to HDL cholesterol. Diabetes Obes Metab 2003; 5: 131–135.

    Article  CAS  PubMed  Google Scholar 

  43. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003; 52: 239–243.

    Article  CAS  PubMed  Google Scholar 

  44. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res 2002; 10: 1104–1110.

    Article  CAS  PubMed  Google Scholar 

  45. Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (London) 2002; 103: 137–142.

    Article  CAS  Google Scholar 

  46. Haque WA, Shimomura I, Matsuzawa Y, Garg A . Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002; 87: 2395.

    Article  CAS  PubMed  Google Scholar 

  47. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815–3819.

    Article  CAS  PubMed  Google Scholar 

  48. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762–769.

    Article  CAS  PubMed  Google Scholar 

  49. Koistinen HA, Vidal H, Karonen SL, Dusserre E, Vallier P, Koivisto VA . Plasma acylation stimulating protein concentration and subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2 diabetic men. Arterioscler Throm Vasc Biol 2001; 21: 1034–1039.

    Article  CAS  Google Scholar 

  50. Weyer C, Tataranni PA, Pratley RE . Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 2000; 23: 779–785.

    Article  CAS  PubMed  Google Scholar 

  51. Pomeroy C, Mitchell J, Eckert E, Raymond N, Crosby R, Dalmasso AP . Effect of body weight and calorie restriction on serum complement proteins, including Factor D/adipsin: studies in anorexia nervosa and obesity. Clin Exp Immunol 1997; 108: 507–515.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Mantov S, Raev D . Addictive effect of diabetes and systemic hypertension on the immune mechanisms of atherosclerosis. Int J Cardiol 1996; 56: 145–148.

    Article  CAS  PubMed  Google Scholar 

  53. Figueredo A, Ibarra JL, Bagazgoitia J, Rodriguez A, Molino AM, Fernandez-Cruz A et al. Plasma C3d levels and ischemic heart disease in type II diabetes. Diabetes Care 1993; 16: 445–449.

    Article  CAS  PubMed  Google Scholar 

  54. Muscari A, Massarelli G, Bastagli L, Poggiopollini G, Tomassetti V, Volta U et al. Relationship between serum C3 levels and traditional risk factors for myocardial infarction. Acta Cardiol 1998; 53: 345–354.

    CAS  PubMed  Google Scholar 

  55. Pickup JC, Crook MA . Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241–1248.

    Article  CAS  PubMed  Google Scholar 

  56. Pickup JC, Mattock MB, Chusney GD, Burt D . NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286–1292.

    Article  CAS  PubMed  Google Scholar 

  57. Rajala MW, Scherer PE . Minireview: the adipocyte – at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003; 144: 3765–3773.

    Article  CAS  PubMed  Google Scholar 

  58. Lyon CJ, Law RE, Hsueh WA . Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144: 2195–2200.

    Article  CAS  PubMed  Google Scholar 

  59. Hotamisligil GS, Spiegelman BM . Tumor necrosis factor α: a key component of the obesity–diabetes link. Diabetes 1994; 43: 1271–1278.

    Article  CAS  PubMed  Google Scholar 

  60. Charlesworth JA, Peake PW, Campbell LV, Pussell BA, O'Grady S, Tzilopoulos T . The influence of oral lipid loads on acylation stimulating protein (ASP) in healthy volunteers. Int J Obesity Rel Metab Disord 1998; 22: 1096–1102.

    Article  CAS  Google Scholar 

  61. Germinario R, Sniderman AD, Manuel S, Pratt S, Baldo A, Cianflone K . Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation stimulating protein. Metabolism 1993; 42: 574–580.

    Article  CAS  PubMed  Google Scholar 

  62. Tao Y, Cianflone K, Sniderman AD, Colby-Germinario SP, Germinario RJ . Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line. Biochim Biophys Acta 1997; 1344: 221–229.

    Article  CAS  PubMed  Google Scholar 

  63. Maslowska M, Sniderman AD, Germinario R, Cianflone K . ASP stimulates glucose transport in cultured human adipocytes. Int J Obesity Rel Metab Dis 1997; 21: 261–266.

    Article  CAS  Google Scholar 

  64. Ahren B, Havel PJ, Pacini G, Cianflone K . Acylation stimulating protein stimulates insulin secretion. Int J Obesity Rel Metab Disord 2003; 27: 1037–1043.

    Article  CAS  Google Scholar 

  65. Ozata M, Gungor D, Turan M, Ozisik G, Bingol N, Ozgurtas T et al. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects. J Clin Endocrinol Metab 2001; 86: 3659–3664.

    Article  CAS  PubMed  Google Scholar 

  66. Ozata M, Ortenli C, Culec M, Ozgurtas T, Bulucu F, Caglar R et al. Increased fasting plasma acylation-stimulating protein concentrations in nephrotic syndrome. J Clin Endocrinol Metab 2002; 87: 853–858.

    Article  CAS  PubMed  Google Scholar 

  67. Halkes CJM, Kijk HV, de Jaegere PPT, Plokker HWM, Van der Helm Y, Erkelens DW et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease effects of expanded-dose simvastatin. Arterioscler Throm Vasc Biol 2001; 21: 1526–1530.

    Article  CAS  Google Scholar 

  68. Zhang XJ, Cianflone K, Genest J, Sniderman AD . Plasma acylation stimulating protein (ASP) as a predictor of impaired cellular biological response to ASP in patients with hyperapoB. Eur J Clin Invest 1998; 28: 730–739.

    Article  CAS  PubMed  Google Scholar 

  69. Sniderman AD, Cianflone K . Metabolic disruptions in the adipocyte–hepatocyte fatty acid axis as causes of hyperapoB. Int J Obesity Rel Metab Disord 1995; 19 (Suppl 1): S27–S33.

    Google Scholar 

  70. Kalant D, Cain SA, Maslowska M, Sniderman AD, Cianflone K, Monk PN . The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein. J Biol Chem 2003; 278: 11123–11129.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by Grant # OOP69600 from CIHR (to KC) and the FRSQ-NSFC Quebec–China exchange program (to KC). KC is Canada Research Chair in Adipose Tissue. We acknowledge the contribution of the Laboratory of Endocrinology and the Laboratory of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology for supporting this work. We thank Lin Feng, Feng Xiao and Jun Wei for technical assistance and for their help in recruiting the subjects. Ping Yin provided statistical advice.

Author information

Authors and Affiliations

  1. Department of Endocrinology, Tongji Hospital, Wuhan, Hubei, P.R. China

    Y Yang, J Zhang, H Y Yu & M X Zhang

  2. Department of Pediatrics, Tongji Hospital, Wuhan, Hubei, P.R. China

    H L Lu, H W Wang & K Cianflone

  3. Centre de Recherche Hôpital Laval, Laval University, Quebec, Canada

    K Cianflone

Authors
  1. Y Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H L Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Y Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H W Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M X Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Cianflone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Cianflone.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, Y., Lu, H., Zhang, J. et al. Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes. Int J Obes 30, 439–446 (2006). https://doi.org/10.1038/sj.ijo.0803173

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0803173

Keywords

This article is cited by

Search

Advanced search

Quick links